title: A partial estrogen receptor agonist with strong antiatherogenic properties without noticeable effect on reproductive tissue in cholesterol-fed female and male rabbits.
abstract: Estrogen replacement therapy retards the development of cardiovascular disease and osteoporosis in postmenopausal women. However, long-term unopposed use increases the risk of cancer in endometrium and possibly in breast. The racemic compound ormeloxifene, widely used in India as an antifertility agent, is a partial estrogen receptor agonist with antiosteoporotic properties. The present study was undertaken to investigate the effect of the L-enantiomer (levormeloxifene) and the d-enantiomer (d-ormeloxifene) on the development of atherosclerosis. In a short-term experiment (6 weeks), 4 x 10 ovariectomized female rabbits were fed a 0.25% cholesterol-enriched diet and the effect on plasma cholesterol levels was studied. In a long-term experiment (13 weeks), 4 x 15 ovariectomized female and 4 x 15 shamoperated male rabbits were maintained at a similar plasma cholesterol level of 25 mmol/L and the effect on undamaged and balloon-injured arterial wall was studied. In both experiments, the rabbits were treated with levormeloxifene, d-ormeloxifene, 17 beta-estradiol, or placebo, respectively. In the short-term experiment, levormeloxifene, in contrast to d-ormeloxifene, significantly reduced plasma cholesterol by 30% compared with the placebo group. In the long-term experiment, levormeloxifene, in contrast to d-ormeloxifene, significantly reduced atherosclerosis by 50% in the undamaged arterial wall of both female and male rabbits. Because these rabbits were cholesterol-clamped, the antiatherogenic effect was not mediated via plasma cholesterol lowering. Like estrogen, levormeloxifene did not inhibit atherosclerosis in the endothelium-denuded site of aorta. The antiatherogenic effects of levormeloxifene were thus similar to those of estrogen, but produced in the absence of any noticeable estrogenic effect on uterine or testicular tissue.
authors.affiliation: Novo Nordisk A/S, Denmark. PHIm@novo.dk
authors.forename: P
authors.initials: P
authors.lastname: Holm
authors.forename: M
authors.initials: M
authors.lastname: Shalmi
authors.forename: N
authors.initials: N
authors.lastname: Korsgaard
authors.forename: B
authors.initials: B
authors.lastname: Guldhammer
authors.forename: S O
authors.initials: SO
authors.lastname: Skouby
authors.forename: S
authors.initials: S
authors.lastname: Stender
mesh_terms: D000818:Animals; D001158:Arteries / Q000187:drug effects; D001161:Arteriosclerosis / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D005260:Female; D007150:Immunohistochemistry; D008297:Male; D011759:Pyrrolidines / Q000494:pharmacology*; D011817:Rabbits; D011960:Receptors, Estrogen / Q000819:agonists*; D013237:Stereoisomerism; D013737:Testis / Q000187:drug effects*; D014599:Uterus / Q000187:drug effects*
chemical_list: D002791:Cholesterol, Dietary; D011759:Pyrrolidines; D011960:Receptors, Estrogen; C108255:levormeloxifene; D002784:Cholesterol